课题基金 / 基金详情

Cyclin-dependent kinases: Novel switches in anergy and targets for tolerance

Cyclin-dependent kinases: Novel switches in anergy and targets for tolerance
细胞周期蛋白依赖性激酶:无反应性的新开关和耐受性目标
批准号:
7627193
负责人:
ANDREW D WELLS
金额:
$41.13万
依托单位国家:
美国
项目类别:
财政年份:
2002
资助国家:
美国
项目状态:
已结题
起止时间:
2002-07-15 至 2013-05-31

项目摘要

项目成果

ANDREW D WELLS的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): T cell anergy is an important mechanism of peripheral tolerance that controls the development of immunopathology in experimental models of autoimmunity and transplantation, and is most likely operative during clinical organ transplantation in humans. Anergy involves the functional inactivation of inappropriate T cell responses, and is thought to be the result of active silencing of effector genes such as interleukin-2 (IL-2). Our progress during the first funding period of this grant established that cell cycle progression is necessary for activated T cells to escape anergy during a productive immune response, and defined a previously unappreciated role for cyclin-dependent kinases (CDK) and their genetically-encoded inhibitory proteins in the decision between T cell immunity and tolerance. The activity of these kinases opposed the induction of T cell clonal anergy in vitro, and genetic dysregulation of CDK activity during organ transplantation interfered with tolerance induced by costimulatory blockade. PUBLIC HEALTH RELEVANCE The goal of this proposal is to explore the molecular mechanisms by which cyclin-dependent kinases regulate T lymphocyte function, and to evaluate the potential of these molecules as therapeutic targets in pre-clinical models of organ transplantation. A deeper understanding of the molecular events underlying T cell tolerance could lead to new approaches to induce tolerance in the setting of autoimmunity and transplantation, and therefore the research proposed in the is application is consistent with and highly relevant to the NIH/HHS goal of improving human health.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
HIPK1: a new immunomodulatory target for SLE
  • 批准号:
    10647292
  • 项目类别:
  • 资助金额:
    $26.7万
  • 财政年份:
    2023
  • 负责人:
    ANDREW D WELLS
  • 依托单位:
Intergenic cis regulatory elements in the control of IL-2 and IL-21
  • 批准号:
    8656204
  • 项目类别:
  • 资助金额:
    $25.2万
  • 财政年份:
    2013
  • 负责人:
    ANDREW D WELLS
  • 依托单位:
Intergenic cis regulatory elements in the control of IL-2 and IL-21
  • 批准号:
    8776923
  • 项目类别:
  • 资助金额:
    $21.0万
  • 财政年份:
    2013
  • 负责人:
    ANDREW D WELLS
  • 依托单位:
Regulation of Foxp3 Function
  • 批准号:
    7875099
  • 项目类别:
  • 资助金额:
    $15.58万
  • 财政年份:
    2009
  • 负责人:
    ANDREW D WELLS
  • 依托单位:
国内基金
海外基金
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
  • 批准号:
    LBY21H010001
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2020
  • 负责人:
    郑绪阳
  • 依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
  • 批准号:
    81703335
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    20.0万元
  • 批准年份:
    2017
  • 负责人:
    卫高菲
  • 依托单位:
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
  • 批准号:
    81670594
  • 项目类别:
    面上项目
  • 资助金额:
    58.0万元
  • 批准年份:
    2016
  • 负责人:
    陈昊
  • 依托单位:
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
  • 批准号:
    81470791
  • 项目类别:
    面上项目
  • 资助金额:
    73.0万元
  • 批准年份:
    2014
  • 负责人:
    董家鸿
  • 依托单位: